扎那米韦(Zanamivir) - 药物靶点：neuraminidase_在研适应症：甲型流感病毒感染，乙型流感病毒感染，流感病毒感染_专利_临床

概要

基本信息

药物类型

小分子化药

别名

4-guanidino Neu5Ac2en、4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid、4-Guanidino-Neu5Ac2en

+ [13]

靶点

neuraminidase

作用机制

neuraminidase抑制剂(神经氨酸苷酶抑制剂)

治疗领域

感染呼吸系统疾病神经系统疾病+ [2]

在研适应症

甲型流感病毒感染乙型流感病毒感染流感病毒感染+ [1]

非在研适应症-

原研机构

GSK Plc

在研机构

GlaxoSmithKline Trading Services Ltd.

GSK PlcGlaxoSmithkline AB

+ [1]

非在研机构-

最高研发阶段批准上市

首次获批日期

瑞典 (1999-06-01)

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C12H20N4O7

InChIKeyARAIBEBZBOPLMB-UFGQHTETSA-N

CAS号139110-80-8

关联

32

项与扎那米韦相关的临床试验

NCT04597437

/ Recruiting临床2期IIT

Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE): A Pilot Randomized Controlled Trial

ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability syndrome which is the main cause of death in dengue fever.

开始日期2024-03-15

申办/合作机构

George Washington University

[+2]

NCT05648448

/ Recruiting临床2期IIT

ADaptive ASsessment of TReatments for influenzA: A Phase 2 Multi-centre Adaptive Randomised Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic Influenza Infection (AD ASTRA)

This trial will use a previously validated platform, to quantitatively assess antiviral effects in low-risk patients with high viral burdens and uncomplicated influenza, to determine in-vivo antiviral activity. In this randomised, open-label, controlled, group sequential, adaptive, platform trial, we will compare the performance of available influenza antivirals, and those with potential activity, relative to the control (no treatment) and each other.
AD ASTRA study is supported by the Wellcome Trust Grant ref: 223195/Z/21/Z through the COVID-19 Therapeutics Accelerator

开始日期2023-02-22

申办/合作机构

University of Oxford

NCT04494412

/ Recruiting临床2期

An Open Label, Single Arm Study to Evaluate Single and Multiple Dose Pharmacokinetics, Safety and Tolerability, and to Explore Clinical Outcomes of Treatment With Intravenous (IV) Zanamivir in Neonates and Infants Under 6 Months of Age With Confirmed Complicated Influenza Infection

Influenza infection is an important public health priority, with seasonal outbreaks and pandemics causing considerable global morbidity and mortality. The PK, pharmacodynamics (PD), safety and efficacy of IV zanamivir have been evaluated in adults, adolescents and infants more than or equal to (>=) 6 months of age with hospitalized influenza in the IV zanamivir global development program. However, antiviral treatment of neonates and infants under 6 months of age hospitalized with influenza infection remains a medical unmet need. Given the immaturity of the immune system at this age, there are no licensed influenza vaccines for children aged less than six months old. As a requirement of the Pediatric Investigation Plan European Union (EU), GlaxoSmithKline (GSK) will be conducting this open-label, multi-center, single arm, post-marketing authorization study to evaluate the PK and collect safety and tolerability information of IV zanamivir in hospitalized neonates and infants under 6 months of age with confirmed complicated influenza infection. The total duration of study participation for each participant will be up to 24 days with a study treatment period up to 10 days and 14 days of post-treatment follow up. However, for a given participant, the initial 5-day treatment course may be extended for up to 5 additional days if clinical symptoms, participant characteristics or virological tests as assessed by the investigator warrant further treatment. DECTOVA is a trademark of GlaxoSmithKline group of companies.

开始日期2022-11-21

申办/合作机构

GSK Plc

100 项与扎那米韦相关的临床结果

登录后查看更多信息

100 项与扎那米韦相关的转化医学

登录后查看更多信息

100 项与扎那米韦相关的专利（医药）

登录后查看更多信息

1,449

项与扎那米韦相关的文献（医药）

2025-03-01·JOURNAL OF INFECTION AND CHEMOTHERAPY

Incidence of severe illness in pediatric influenza outpatients treated with baloxavir or neuraminidase inhibitors

Article

作者: Takahashi, Yusaku ; Ogura, Eriko ; Miyairi, Isao ; Kitanishi, Yoshitake ; Kojima, Satoshi ; Miyazawa, Shogo

INTRODUCTION:

A single oral dose of baloxavir marboxil, a cap-dependent endonuclease inhibitor, is approved for patients with influenza A or B infection; however, real-world evidence is limited. We evaluated the effectiveness of baloxavir vs neuraminidase inhibitors in reducing the incidence of severe illness in influenza outpatients aged 5-11 years.

METHODS:

In this retrospective cohort study, we analyzed individual-level data from patients treated with these antivirals, using a large, Japanese health insurance claims database (JMDC). Patients were included at the first date of diagnosis of the influenza virus infection (Day 1) in two influenza seasons. The primary outcome was the incidence of hospitalization from Day 2-14.

RESULTS:

Of 196,749 included patients (Season 2018/2019, n = 103,709; Season 2019/2020, n = 93,040), 20.9 % received baloxavir, 38.8 % received oseltamivir, 28.7 % received laninamivir, and 11.6 % received zanamivir. In each treatment group, 61-70 % patients had influenza A. The incidence of hospitalization from Day 2-14 was significantly lower for baloxavir than for oseltamivir, laninamivir, and zanamivir. The adjusted risk ratio (95 % CI) for oseltamivir, laninamivir, and zanamivir were 1.86 (1.30-2.68), 2.11 (1.37-3.25), and 1.90 (1.31-2.77), respectively, compared with baloxavir. Comparative incidence of hospitalizations between agents were unaffected by season or virus type.

CONCLUSION:

Using a large, Japanese health insurance claims database, a lower rate of hospitalization was demonstrated in children aged 5-11 years with an influenza virus infection when treated with baloxavir vs neuraminidase inhibitors. Thus, single dose, oral baloxavir may reduce the incidence of severe illness in these patients.

2025-03-01·JOURNAL OF INFECTION AND CHEMOTHERAPY

In vitro neuraminidase inhibitory concentrations (IC50) of four neuraminidase inhibitors in the Japanese 2023–24 season: Comparison with the 2010–11 to 2022–23 seasons

Article

作者: Bando, Takuma ; Kawai, Naoki ; Tani, Naoki ; Ikematsu, Hideyuki ; Chong, Yong ; Goto, Takeyuki ; Sato, Tomonori

INTRODUCTION:

To assess the susceptibility of epidemic influenza viruses to the four most used neuraminidase inhibitors (NAIs) during the 2023-24 influenza season in Japan, we measured the 50 % inhibitory concentration (IC₅₀) of oseltamivir, peramivir, zanamivir, and laninamivir in virus isolates from the sample of 100 patients.

METHODS:

Viral isolation was done using specimens obtained before and after treatment, with the type/subtype determined by RT-PCR using type- and subtype-specific primers. IC₅₀ values were determined by a neuraminidase inhibition assay using a fluorescent substrate.

RESULTS:

The virus isolates included 16 A(H1N1)pdm09, 19 A(H3N2), and 65 B/Victoria-lineage. The geometric mean (GM) IC₅₀ values of pre-treatment samples for oseltamivir, peramivir, zanamivir, and laninamivir were 0.90 nM, 0.62 nM, 1.09 nM, and 2.77 nM for A(H1N1)pdm09; 0.86 nM, 0.67 nM, 1.64 nM, and 3.61 nM for A(H3N2); and 16.12 nM, 1.84 nM, 3.87 nM, and 11.35 nM for B/Victoria, respectively. These values were comparable to those from the previous eleven seasons, and no virus with significantly reduced susceptibility to any of the NAIs was found either before or after drug administration in the 2023-24 season.

CONCLUSIONS:

These results indicate that susceptibility to these four NAIs has been maintained across the three influenza types/subtypes over the past fourteen seasons in Japan.

2025-01-01·Fukushima Journal of Medical Science

Pharmacologic background and clinical issue of anti-influenza drugs

Review

作者: Sato, Masatoki

Since 2000, rapid antigen detection kits and anti-influenza drugs have been used for the early diagnosis and treatment of influenza in Japan, respectively.　The main drugs available in clinical practice are the neuraminidase inhibitors oseltamivir, zanamivir, laninamivir, and peramivir, as well as the cap-dependent endonuclease inhibitor baloxavir marboxil.　Antiviral therapy with neuraminidase inhibitors has been practiced for many years, especially in Japan; it can shorten the febrile period and reduce complications.　Despite having similar structures, the pharmacologic background of neuraminidase inhibitors differs significantly, as reflected in their varying clinical efficacy.　Due to its inhibitory mechanism, baloxavir marboxil can rapidly reduce the viral load than neuraminidase inhibitors.　However, the duration of symptoms was similar after the administration of baloxavir marboxil and oseltamivir, and variants with reduced drug susceptibility have been detected in 20%-30% of pediatric patients treated with baloxavir marboxil.　Clinical trials of several novel anti-influenza drugs are currently underway.　When these drugs are first marketed, the characteristics of the influenza virus and the pharmacologic background of the drugs must be clarified before their administration to patients in clinical practice.

69

项与扎那米韦相关的新闻（医药）

2025-01-22

·生物谷

对抗流感的“神药”靠谱吗？JAMA子刊｜抗病毒药物「巴洛沙韦」更有希望缩短高危流感患者的症状持续时间

在一项由山东大学领导的新研究中，研究人员对多种抗病毒药物治疗非严重流感的效果进行了系统评价和荟萃分析。研究结果表明，巴洛沙韦（baloxavir，商品名速福达）可能成为高危患者的一个秘密武器，因为它不仅能缩短症状持续时间，还可能降低住院风险，并且不会增加不良事件的风险。相关研究结果于2025年1月13日在线发表在JAMA Internal Medicine期刊上，论文标题为“Antiviral Medications for Treatment of Nonsevere Influenza: A Systematic Review and Network Meta-Analysis”。流感是一种每年影响数百万人的病毒性呼吸道疾病，其严重并发症可能导致致命后果。为了应对这种威胁，科学家们开发了不同的抗病毒药物，它们各自有着独特的能力来对付流感病毒：神经氨酸酶抑制剂，如奥司他韦（oseltamivir，商品名达菲）和扎那米韦（zanamivir，商品名瑞乐砂），通过阻止病毒在细胞间传播来缓解症状。内切酶抑制剂，如巴洛沙韦（baloxavir，商品名速福达），则专门攻击病毒复制遗传物质的能力。巴洛沙韦：脱颖而出的“新星” 在这场与流感的战斗中，巴洛沙韦之所以引人注目，是因为它在某些方面表现得比其他抗病毒药物更为出色。根据这项荟萃分析，巴洛沙韦可能会将症状持续时间缩短大约一天（1.02天），对于高危患者来说，这不仅意味着更快地恢复健康，还可能减少住院的风险。而且，使用巴洛沙韦并不会增加不良事件的发生率，这对于担心副作用的人来说是个好消息。具体而言，为找出最有效的治疗方法，研究人员从MEDLINE、Embase、CENTRAL等数据库中收集了73项随机临床试验的数据，涉及超过34,000名参与者。他们评估了死亡率、住院率、症状缓解和不良事件等结果，并使用GRADE（Grading of Recommendations Assessment, Development, and Evaluation, 建议评估、开发和评价分级）方法评估证据的确定性。这种系统性方法根据偏差风险、结果的一致性、证据的直接性和估计的准确性等因素评估证据的质量。这一框架有助于确定研究结果的强度及其对临床决策的可靠性。研究表明，巴洛沙韦在缩短症状持续时间和降低高危患者的住院风险方面具有潜在的优势，尽管这一结论的确定性级别有所不同。对于低风险和高风险患者，巴洛沙韦对死亡率的影响很小或几乎没有影响，这是一个重要的发现。此外，虽然巴洛沙韦与约10%的耐药性出现风险有关，但与安慰剂相比，它引起的不良事件较少。相比之下，奥司他韦对死亡率和住院率几乎没有影响，但它确实能平均减少0.75天的症状持续时间。然而，使用奥司他韦可能会增加不良事件的风险。至于其他抗病毒药物，如扎那米韦、拉尼米韦（laninamivir）和阿比朵尔（umifenovir），它们的效果不一致或不确定，证据的质量从中等到极低不等。未来的探索之路尽管这项研究提供了宝贵的信息，但它也指出了未来研究需要填补的一些空白。特别是在重症监护室入院、住院时间和抗病毒药物耐药性等方面，还需要更多的具体患者结局数据。因此，科学家们将继续努力，寻找更多关于如何更好地保护我们免受流感侵害的答案。参考资料： Ya Gao et al. Antiviral Medications for Treatment of Nonsevere Influenza: A Systematic Review and Network Meta-Analysis. JAMA Internal Medicine , 2025, doi:10.1001/jamainternmed.2024.7193. Flu antiviral baloxavir shows promise over other treatments for high-risk patients, shortening symptom durationhttps://medicalxpress.com/news/2025-01-flu-antiviral-baloxavir-treatments-high.html 本文仅用于学术分享，转载请注明出处。若有侵权，请联系微信：bioonSir 删除或修改！点击下方「阅读原文」，前往生物谷官网查询更多生物相关资讯~

临床研究临床结果

2025-01-22

·赛柏蓝

刚刚｜2025年版流感诊疗方案发布

编辑 | 凯西来源 | 赛柏蓝刚刚，国家卫生健康委办公厅、国家中医药局综合司发布《关于印发流行性感冒诊疗方案（2025年版）的通知》。此版诊疗方案主要对以下内容进行了修订完善：进一步完善了发病机制、病理以及临床表现，增加了临床轻型和中型分型，完善了重型和危重型标准，细化了抗病毒治疗原则以及重症病例呼吸、循环等支持治疗措施，对中医辨证治疗予以调整优化。据赛柏蓝梳理，《流行性感冒诊疗方案（2025 年版）》（文末附完整版）在抗病毒治疗中提到的药物有：神经氨酸酶抑制剂奥司他韦、帕拉米韦、扎那米韦，和RNA 聚合酶抑制剂玛巴洛沙韦、法维拉韦。在中医药治疗部分，除基本方药外，《流行性感冒诊疗方案（2025 年版）》提出可按照辨证施治原则根据药品说明书选用相应中成药。附：《流行性感冒诊疗方案（2025 年版）》 END 内容沟通：郑瑶（13810174402）

2025-01-19

·药事纵横

全程仅需一次口服，儿童版“超级抗流感药”—玛巴洛沙韦干混悬剂产品分析

1、概述恰逢流感高发期，儿童医院人满为患。现结合前期文献调研，并结合相关经验，对超级抗流感药玛巴洛沙韦干混悬剂进行产品分析，以期对读者有所启发。在玛巴洛沙韦获批之前，市面上仅有两类流感抗病毒药物可用：一种是M2阻断剂（金刚烷胺和金刚乙胺），另一种是神经氨酸酶抑制剂（NAI：奥司他韦、扎那米韦和帕拉米韦）。玛巴洛沙韦为选择性抑制帽状结构依赖性核酸内切酶的前药，是FDA近20年来首个且唯一批准的全新作用机制的抗流感病毒药物，全程一次口服，起效快、更安全、顺应性好，其片剂已在全球多个国家和地区上市用于流感的治疗和暴露后预防，单次口服的给药方式也获得临床认可，较其他已上市流感治疗药物给药更加便捷。Roche Pharma (Schweiz) AG按化药5.1类申请玛巴洛沙韦干混悬剂进口上市，规格40mg/20mL (2mg/mL)，生产厂Shionogi Pharma Co.,Ltd.，包装厂F. Hoffmann-La Roche AG（瑞士），注册代理为罗氏（中国）投资有限公司，按照优先审评审批程序进行审评（儿童用药），适用于儿童单纯性甲型和乙型流感患者，于2023年12月29日获得国家药监局批准。干混悬剂方便低龄儿童及无法吞咽片剂的患者临床用药，本品已纳入《临床急需境外新药名单（第三批）》，如下表：目前无仿制产品获批，且该化合物及产品仍在专利期内。下面对该品种的处方及质量控制进行介绍，以期对大家有一定的指导意义。 2、处方概述玛巴洛沙韦干混悬剂商品名为速福达，为“超级达菲”，整个疗程仅需1次给药，极大提高患者的顺应性。现结合中欧美国家公开的审评报告，对本品的处方工艺信息进行介绍。原料药简介：首先是原料药玛巴洛沙韦，其分子量为571.55，分配系数（LogP）为2.26，易溶于二甲基亚砜，溶于乙腈，微溶于甲醇和乙醇，几乎不溶于水。该原料药溶解性不好，其溶解性与pH值无关，一般情况需控制粒度，以保证产品溶出度符合要求。该原料药有2个手性中心，需关注其手性异构体情况。辅料信息：该干混悬剂处方中辅料为甘露醇、麦芽糖醇、氯化钠、羟丙甲纤维素、聚维酮K25、三氯蔗糖、胶态二氧化硅、滑石粉、草莓香精。草莓香精为矫味剂，为改善儿童的口服顺应性而加入，需关注各辅料用量的合理性，同时需关注草莓香精中可能含有的小分子醛类杂质。按照80mg的最大日剂量对处方中各辅料用量的安全性进行评估，处方中各辅料的用量均需符合相关法规要求（如FDA非活性物质数据库），草莓香精是非法定辅料，可能需要提供毒理学数据来证明其用量的合理性。过量灌装：本品包装在带防儿童窃启螺盖的琥珀色玻璃瓶中，单剂量包装，最大日剂量80mg，其具体使用方法：该产品必须使用20mL水进行分散，制备成2mg/mL的混悬液。FDA审评报告显示本品有过量灌装，该过量灌装已经过抽取试验验证（保证不低于20ml的抽取量）。 3、质量控制 FDA的审评报告显示本品的关键质量属性包括形状（干混悬剂及配制后混悬液）、鉴别、干混悬剂含量及含量均一性、配制后混悬液含量及含量均一性、有关物质、溶出度、含量均匀度、微生物限度。FDA审评过程中性状发生过变更，主要是针对配制后混悬液的性状，即配制后的混悬液是具有草莓味的灰白色、白色至浅黄色的不透明混悬液；而干混悬剂的性状为白色至浅黄色颗粒。EMA审评报告中显示放行标准和货架期标准中检测项包括：瓶内容物性状（目视）、配制后的混悬液性状（目视）、配制时间（目视）、分散均匀性（Ph. Eur.）、鉴别（UHPLC、UV）、每瓶含量（HPLC）、有关物质（HPLC）、水分（Ph. Eur.）、溶出度（Ph. Eur.，UV）、剂量单位均匀度（Ph. Eur. ，UHPLC）和微生物限度（Ph.Eur.）。FDA和EMA关于本品的质量控制项目基本一致。使用中稳定性研究：由于本品处方中不含防腐剂，制备成混悬液后可在20~25℃下保存10小时，该保存时间需经过微生物挑战试验的验证，FDA审评报告显示该混悬液在放置10小时后微生物开始出现。溶出度：FDA溶出度数据库中显示本品的溶出具体信息如下表所示：本品采用桨法，25rpm，进行溶出度测定。溶出度测定条件需要有一定的区分力，比如区分不同的原料药粒度大小，即不同的原料药粒度，其溶出行为可能表现出一定的差异。有关物质：其质控限和鉴定限等需符合ICH相关要求。元素杂质：基于80mg的最大日剂量，拟定合理的控制策略，同时需符合ICH Q3D的相关要求。混悬液的制备方法：轻叩瓶底，使药物颗粒松动；用20mL饮用水或无菌水分散该干混悬剂；缓慢旋晃药瓶，使颗粒均匀混悬（不要振摇药瓶，振摇会产生泡沫，导致剂量抽取不准确）；确保10h内使用。关于上述混悬液的使用方法需要相容性研究和微生物挑战试验支持。本品适用于不能吞咽或吞咽困难的患者，或者可通过鼻饲管给药，给药前后均使用1mL水冲洗。针对鼻饲管给药，申请人需参照相关技术指导原则开展体外对比研究，以支持该给予方式。贮藏：干混悬剂的贮藏条件为“密闭，不超过25℃。”配制后的混悬液置于30℃或以下，并在配置后2h内服用。如未能在2h内服用或药液的暴露温度超过30℃，请勿服用。需提供相应的稳定性研究数据以支持拟定的贮藏条件。 4、小结玛巴洛沙韦干混悬剂适用于儿童，全程仅需一次给药，极大提高了患者的顺应性。目前该产品仍在专利期，无仿制产品申报。本文结合前期文献调研，对其处方及质量研究进行分析，以期为后续仿制药申报提供一定的参考。参考文献 FDA审评报告 EMA审评报告中国公开审评报告药事纵横征稿启事

优先审批申请上市

100 项与扎那米韦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00902	扎那米韦	J05AH01	DB00558

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
甲型流感病毒感染	欧盟	GlaxoSmithKline Trading Services Ltd.	2019-04-26
甲型流感病毒感染	冰岛	GlaxoSmithKline Trading Services Ltd.	2019-04-26
甲型流感病毒感染	列支敦士登	GlaxoSmithKline Trading Services Ltd.	2019-04-26
甲型流感病毒感染	挪威	GlaxoSmithKline Trading Services Ltd.	2019-04-26
乙型流感病毒感染	欧盟	GlaxoSmithKline Trading Services Ltd.	2019-04-26
乙型流感病毒感染	冰岛	GlaxoSmithKline Trading Services Ltd.	2019-04-26
乙型流感病毒感染	列支敦士登	GlaxoSmithKline Trading Services Ltd.	2019-04-26
乙型流感病毒感染	挪威	GlaxoSmithKline Trading Services Ltd.	2019-04-26
流感病毒感染	美国	GSK Plc	1999-07-26

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
关节痛	临床2期	荷兰	GSK Plc	2022-11-21
关节痛	临床2期	波兰	GSK Plc	2022-11-21
关节痛	临床2期	西班牙	GSK Plc	2022-11-21
关节痛	临床2期	英国	GSK Plc	2022-11-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01527110 (115215, CTgov)	临床3期	甲型流感病毒感染	21	Zanamivir	築醖淵積醖憲鏇餘範憲(簾製齋齋鏇築構鹽憲觸) = 鹽簾蓋鏇鏇獵淵網衊網鏇蓋憲夢鬱鏇糧襯簾蓋 (製製蓋鑰網鑰淵憲衊醖, 製範鬱衊襯繭壓淵築鬱 ~ 餘糧夢簾憲鑰範鏇鹽膚) 更多	-	2018-02-22
NCT01231620 (ZORO, CTgov)	临床3期	流感病毒感染	626	Placebo to match oseltamivir+Zanamivir (Intravenous (IV) Zanamivir 300mg Twice Daily)	鏇艱蓋築鑰鬱鬱鏇範鹽(鏇齋膚獵廠餘積獵窪襯) = 築齋鑰繭築網顧積鬱蓋淵積繭醖範夢壓醖膚壓 (獵範廠網獵鹹積壓鹹壓, 膚壓鹹齋醖齋衊壓製獵 ~ 鬱築製積壓積壓範憲蓋) 更多	-	2017-11-20
				Placebo to match oseltamivir+Zanamivir (Intravenous (IV) Zanamivir 600mg Twice Daily)	鏇艱蓋築鑰鬱鬱鏇範鹽(鏇齋膚獵廠餘積獵窪襯) = 廠築襯鏇鹹築獵夢醖餘淵積繭醖範夢壓醖膚壓 (獵範廠網獵鹹積壓鹹壓, 廠壓網淵鑰構顧膚觸襯 ~ 築鑰艱淵願淵鑰築網範) 更多
NCT01014988 (CTgov)	临床2期	流感病毒感染	202	zanamivir (Cohort 6: Adults (18 Years and Older))	衊範艱繭築夢餘醖膚獵(廠壓積餘顧顧膚鏇鹽餘) = 鑰製顧鬱餘築鹽顧鹽憲憲衊鏇觸簾糧艱壓齋鬱 (衊鏇遞願襯鏇構醖淵夢, 襯餘獵範壓獵繭壓膚獵 ~ 範廠選廠構齋簾鏇鹽製) 更多	-	2017-03-28
				zanamivir (Cohorts 1-5: Pediatrics/Adolescents (6 Months to <18 Years))	衊範艱繭築夢餘醖膚獵(廠壓積餘顧顧膚鏇鹽餘) = 顧選齋網艱選餘顧鹽觸憲衊鏇觸簾糧艱壓齋鬱 (衊鏇遞願襯鏇構醖淵夢, 遞艱餘遞衊簾遞構範願 ~ 窪網簾糧齋遞蓋糧鑰窪) 更多
NCT01527110 (115215, Pubmed \| Curr Opin Pulm Med \| Antivir Ther) 人工标引	临床3期	流感病毒感染	21	zanamivir	製夢糧遞願蓋夢廠鑰餘(積獵淵獵選範構積獵鑰) = 觸範鹽選齋淵醖鏇獵構鏇鏇憲遞網積衊鏇獵觸 (築網製網鬱餘齋鏇鬱鹽 ) 更多	积极	2015-01-01
NCT01014988 (Pubmed \| J Infect Dis)	临床2期	流感病毒感染	-	Intravenous Zanamivir 600 mg	夢糧衊夢齋網觸鹹壓鏇(構顧膚鬱獵衊醖鬱獵鏇) = 鬱簾糧淵願膚範製餘憲襯顧衊壓鏇艱艱膚醖範 (衊簾鹽醖築廠鑰遞繭夢 ) 更多	-	2014-02-15
NCT00799760 (Pubmed \| Clin Microbiol Infect)	临床3期	甲型流感病毒感染	541	Oseltamivir	醖鹽齋蓋鬱構鏇蓋繭壓(簾憲衊鏇廠膚遞遞網築) = 願憲夢範憲醖遞積構網網觸選選鬱鏇鹽窪憲夢 (鹽鑰積觸遞齋築鹽選膚 )	-	2013-02-01
				Zanamivir	醖鹽齋蓋鬱構鏇蓋繭壓(簾憲衊鏇廠膚遞遞網築) = 鬱網膚繭鏇廠網鏇獵艱網觸選選鬱鏇鹽窪憲夢 (鹽鑰積觸遞齋築鹽選膚 )
NCT00784784 (Stop-Flu-2, CTgov)	临床3期	流感病毒感染	64	Fluviral (Influenza Vaccine)	願窪鹽顧鏇壓廠醖願蓋(簾鑰醖遞憲遞醖鹽壓簾) = 網淵餘顧網網範醖製構選膚衊積壓顧網範壓糧 (繭鑰願廠壓窪壓齋選網, 繭衊廠鑰構憲餘繭衊構 ~ 淵網築齋築鹽鬱積醖鑰) 更多	-	2011-09-02
				Zanamivir (Antiviral Prophylaxis)	願窪鹽顧鏇壓廠醖願蓋(簾鑰醖遞憲遞醖鹽壓簾) = 廠憲壓襯獵鹹醖齋鑰夢選膚衊積壓顧網範壓糧 (繭鑰願廠壓窪壓齋選網, 齋糧顧夢膚築壓艱襯構 ~ 夢獵獵簾醖範範衊醖鹽) 更多